Therapeutic Advances in Gastroenterology, Volume 19, January-December 2026.
Although immune checkpoint inhibitors have revolutionized oncologic therapy, they are frequently associated with a wide spectrum of immune-related adverse events, most notably immune-mediated colitis (ImC). For cases of moderate-to-severe colitis, ...